High Levels of Vitamin C Prove Toxic to HIV

March 04, 1997

NEW YORK, N.Y., February 28, 1997 -- Laboratory research by Memorial Sloan-Kettering Cancer Center scientists shows that HIV-infected immune cells take in more vitamin C and glucose than their healthy counterparts, which may aid replication of the AIDS virus. At the same time, however, extremely high levels of the vitamin are more toxic to the HIV-infected cells than to healthy immune cells, the investigators report in the Feb. 28 issue of the Journal of Biological Chemistry.

³HIV-infected cells grown in the laboratory appear to be more sensitive to the toxic effects of vitamin C,² explained Dr. David W. Golde, Physician-in-Chief of Memorial Hospital and senior author of the paper. ³At the same levels of exposure, the HIV-infected cells took in more vitamin C than uninfected immune cells.²

The laboratory research provides the foundation to begin to understand the relationship among vitamin C, HIV infection, and cell metabolism, and may lead to new therapeutic targets to counter the AIDS virus, he added. Vitamin C is essential to the human body and is necessary for normal function of the immune system.

The researchers studied vitamin C uptake and its effects on AIDS-virus production in HIV-infected and healthy immune cells, after finding in previous studies that cancer cells also take in more glucose and vitamin C than normal cells. In addition, Dr. Golde and his colleagues were the first to prove, in 1993, that the same molecule that allows glucose into cells also serves as a route for vitamin C to enter. Although vitamin C is used by cells in one chemical form (ascorbic acid), it enters cells in another form (dehydroascorbic acid). Once inside the cell, this vital nutrient is reconverted to its original form, whose different shape and size prevent it from leaving the cell.

This series of studies prompted Dr. Golde and his colleagues to ask whether HIV-infected cells also take in higher-than-normal levels of glucose and vitamin C. In the new study, led by Dr. Coralia Rivas and Dr. Juan Carlos Vera of Memorial Sloan-Kettering¹s Molecular Pharmacology and Therapeutics Program, the researchers studied the effects of vitamin C in four HIV-infected cell lines and four identical, but uninfected, immune cell lines. They found that compared with the healthy cells, the HIV-infected cells:³We noticed that shortly after infection with HIV, the cells put out more glucose-transport molecules on their surfaces, which allow more vitamin C to enter,² Dr. Golde said. ³HIV-infected cells seem to want more glucose and vitamin C. But if they take in too much vitamin C, they die.²

When the researchers exposed both HIV-infected and healthy immune cells to varying levels of vitamin C, they observed a range of effects. At levels of vitamin C comparable to those normally found in the body, the nutrient either had no effect or caused a slight increase in viral replication. But exposure to high vitamin C levels ‹ more than 20 times greater than normal ‹ decreased replication of the AIDS virus and was generally more toxic to HIV-infected cells than to the uninfected cells.

Such high blood levels of vitamin C can¹t be achieved by taking it orally because most supplemental vitamin C is excreted in the urine, Dr. Golde said. He and his colleagues are planning follow-up studies of vitamin C¹s effects in patients infected with the AIDS virus.

Memorial Sloan-Kettering Cancer Center is the world¹s oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Throughout its long, distinguished history, the Center has played a leadership role in defining the standard of care for patients with cancer. In 1996, Memorial Sloan-Kettering was named the nation¹s best cancer center for the fourth consecutive year by U.S. News & World Report.
-end-


Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.